RE:RE:RE:RE:Q3 resultsMrMugsy wrote: Yes ... we are here to learn.
But ... more importantly, you have to trust Goodman's approach or this investment wouldn't make much sense to the small investor. Without trust, Goodman would never have been afforded enough time or latitude to build a successful ROW. There's a reason people don't build ROW, most shareholders wouldn't give you the time needed. In this case, Goodman has been promised time and the shares have spoken at every AGM. Goodman asked for 10 years and the bulk of investors have accepted that. No amount of complaining will change that. How do I know that? Meir's failure and voting at every AGM has proven that the shares are standing tall beside Goodman - they are trusting him.
That last comment is very important for anyone wondering why Goodman hasn't been kicked out - why shareholders aren't voting against Goodman. Investors have strongly given Goodman the support he needs to carry out this ROW task.
My comments should not be construed as me being happy - but I get it, as should those who say Goodman is going to be fired. That's just not realistic.
Some equate my comments as me being happy with the share price. Not true. But it is what it is. I have no doubts Goodman is on the right track.
In terms of M8 Pharma, we own 5% of outstanding shares. We are also considering lending them $100M USD more as M8 is heading into a Janssen deal. It would be nice to know if that partnership is strong or if it's weakened because of the GBT purchase. It would give us an idea of how quickly (or how slowly) we are going to move into other geographies like Mexico or Central America via the BioPas Labs partnership with M8.
Really, what I want to know is ... how much ownership do we get if we lend M8 more money? I think we want to grow that ownership and exert more control in LATAM. Just a thought.
All in my opinion.
Moksha8 is only a $ 12 M loan for now. The nature of the futur relation is 100 % speculation, IMO.